中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2015年
8期
78-80
,共3页
王玉琳%刘晶%尤香贵%尹立勇%张亚杰%崔志杰
王玉琳%劉晶%尤香貴%尹立勇%張亞傑%崔誌傑
왕옥림%류정%우향귀%윤립용%장아걸%최지걸
双联抗血小板药物%急性脑梗死%扣针蛋白5%管性血友病因子%P-选择素%不良反应
雙聯抗血小闆藥物%急性腦梗死%釦針蛋白5%管性血友病因子%P-選擇素%不良反應
쌍련항혈소판약물%급성뇌경사%구침단백5%관성혈우병인자%P-선택소%불량반응
dual antiplatelet drugs%acute cerebral infarction%fibulin-5%vWF%P-selectin%adverse reactions
目的：探讨双联抗血小板药物对急性脑梗死患者血清中扣针蛋白5（Fibulin－5）、管性血友病因子（vWF）和P－选择素（P－selectin）的影响。方法收集秦皇岛市第一医院收治的急性脑梗死患者60例，随机分为对照组和实验组，每组各30例，在常规治疗基础上，对照组给予阿司匹林口服治疗，实验组在对照组治疗基础上加用氯吡格雷口服治疗。治疗结束后，对所有患者的血清Fibulin－5、vWF和P－选择素水平及不良反应情况进行检测。结果治疗后，与对照组比较，实验组患者的血清Fibulin－5水平明显较低（P＜0．05）；实验组患者的血清vWF水平明显较低（P＜0．05）；实验组患者的血清P－selectin水平明显较低（P＜0．05）；2组患者不良反应的发生率无明显差异。结论双联抗血小板药物能够降低急性脑梗死患者血清中Fibulin－5、vWF和P－selectin，不良反应未见明显增加，对临床有指导意义。
目的：探討雙聯抗血小闆藥物對急性腦梗死患者血清中釦針蛋白5（Fibulin－5）、管性血友病因子（vWF）和P－選擇素（P－selectin）的影響。方法收集秦皇島市第一醫院收治的急性腦梗死患者60例，隨機分為對照組和實驗組，每組各30例，在常規治療基礎上，對照組給予阿司匹林口服治療，實驗組在對照組治療基礎上加用氯吡格雷口服治療。治療結束後，對所有患者的血清Fibulin－5、vWF和P－選擇素水平及不良反應情況進行檢測。結果治療後，與對照組比較，實驗組患者的血清Fibulin－5水平明顯較低（P＜0．05）；實驗組患者的血清vWF水平明顯較低（P＜0．05）；實驗組患者的血清P－selectin水平明顯較低（P＜0．05）；2組患者不良反應的髮生率無明顯差異。結論雙聯抗血小闆藥物能夠降低急性腦梗死患者血清中Fibulin－5、vWF和P－selectin，不良反應未見明顯增加，對臨床有指導意義。
목적：탐토쌍련항혈소판약물대급성뇌경사환자혈청중구침단백5（Fibulin－5）、관성혈우병인자（vWF）화P－선택소（P－selectin）적영향。방법수집진황도시제일의원수치적급성뇌경사환자60례，수궤분위대조조화실험조，매조각30례，재상규치료기출상，대조조급여아사필림구복치료，실험조재대조조치료기출상가용록필격뢰구복치료。치료결속후，대소유환자적혈청Fibulin－5、vWF화P－선택소수평급불량반응정황진행검측。결과치료후，여대조조비교，실험조환자적혈청Fibulin－5수평명현교저（P＜0．05）；실험조환자적혈청vWF수평명현교저（P＜0．05）；실험조환자적혈청P－selectin수평명현교저（P＜0．05）；2조환자불량반응적발생솔무명현차이。결론쌍련항혈소판약물능구강저급성뇌경사환자혈청중Fibulin－5、vWF화P－selectin，불량반응미견명현증가，대림상유지도의의。
Objective To analyse the effect of dual antiplatelet drugs on fibulin-5, vWF and P-selection in serum of patients with acute cerebral infarction.Methods Diagnosed 60 patients with acute cerebral infarction in our hospital and collected. All patients were randomly divided into experimental group and control group, 30 cases in each group.The control group was treated with conventional treatment and aspirin, and the experimental group was treated with clopidogrel on the basis of control group.After treatment, the serum levels of Fibulin-5, vWF, P-selection and adverse reactions were detected in all patients.ResuIts After treatment, compared with control group, the serum Fibulin-5 level was significantly lower in experimental group ( P<0.05 );the serum vWF level in experimental group was significantly lower ( P<0.05 );the serum P-selectin level in experimental group was significantly lower (P<0.05);there was no significant difference in the incidence of adverse reactions between two groups. ConcIusion Dual antiplatelet drugs can reduce serum vWF, P-selectin and fibulin-5 in serum of patients with acute cerebral infarction, adverse reactions do not significantly increase, have guiding significance to clinical application.
